杂志简称：int j gynecol cancer
中文译名：《国际妇科癌症杂志》
收录属性：高质量科技期刊（t3）, scie（2024版）, 目次收录（维普）,英文期刊,
自引率：11.90%
投稿方向：医学、obstetrics & gynecology 妇产科学、oncology 肿瘤学
SCI/E期刊基本信息
出版周期：月刊 地区：美国
中科院分区：3区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：非OA期刊
国际标准刊号：ISSN1048-891X；EISSN1525-1438
杂志语言：英语
出版国家：美国
杂志官网 联系方式
出版地址：LIPPINCOTT WILLIAMS & WILKINS,530 WALNUT ST,PHILADELPHIA,USA,PA,19106-3621
杂志邮箱：
投稿网址：https://mc.manuscriptcentral.com/ijgcancer
杂志官方网址：https://ijgc.bmj.com/
出版商网址：http://www.bmjjournals.com
杂志投稿要求
投稿须知【杂志社官方网站信息】
For authors
International Journal of Gynecological Cancer (IJGC), the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.
Questions? Contact ijgc@jjeditorial.com
Submission Policies
For guidelines on policy and submission across our journals, please click on the links below:
Manuscript Preparation
Editorial Policies
Patient Consent Forms
License Forms
Peer Review
Submission and Production Processes
Authors may find it useful to consult our pre-submission checklist. Please review the article type requirements below and the Author Guide, prior to submitting your manuscript or revision.
Copyright and Licensing
Articles are published under an exclusive licence (or non-exclusive license for UK Crown and US Federal Government employees) and authors retain copyright. Articles can also be published under a Creative Commons license to facilitate reuse of the content; please refer to the International Journal of Gynecological Cancer Copyright Author License Statement.
Institutional Review Board Approval
Every research article, including every submitted article involving human participants, requires a statement of ethical or institutional review board approval within the manuscript text. Furthermore, a formal letter of ethical or institutional review board approval must be uploaded along with the manuscript files at initial submission.
In addition, please note that all manuscripts reporting clinical research on human subjects must state in the first paragraph of the Methods section that: 1) The study was approved by the appropriate Institutional Review Board (IRB), and 2) written informed consent was obtained from all subjects, a legal surrogate, the parents or legal guardians for minor subjects, or the requirement for written informed consent was waived by the IRB.
For the above, please state whether written informed consent was obtained from all subjects. If written informed consent was not obtained, please state whether the requirement for written informed consent was waived by the IRB.
Find more information about ethical approval.
Author’s Response
When submitting a revision, please include an Author’s Response to the reviewers’ comments. Please list each comment from each reviewer and provide a point-by-point response indicating how the comment has been addressed and the specific page(s) and line number(s) where the change was made in the manuscript text file. Additionally, please copy and paste the changed text in the Author’s Response.
An example is below:
Reviewer 1, Comment 1: Please clarify what you mean by “borderline pathology.”
Author’s Reply: We have clarified this in the Methods section on page 6, lines 4-5.
Modified Text: “Patients with borderline mucinous and serous tumors were more likely to be partially satisfied, not satisfied or not at all satisfied compared to patients with cancer (p=0.027).”
Please note that authors may be required to provide data or cited works upon request for purposes of peer review.
Abbreviations
Abbreviations cannot be used and must be spelled out at each use (including the title, abstract, and main text) for all terms. If a submission contains abbreviations, it will be returned to the author for all abbreviations to be spelled out through the submission prior to review. The only allowed exceptions to this rule are listed below:
Abbreviations are always allowed for:
Units of measure
Clinical trial names
Any name of a gene (e.g., BRCA) or serologic market (e.g., CA125)
Abbreviations are allowed but must be spelled out at first use for:
Statistical terms (SPSS, Stata)
The following organizations: NCI, WHO, FDA, CDC
The following terms: HPV, Pap, MRI, USG, CT, PET/CT, HNPCC, HIPEC, RIFLE, FDG, EGOG, SLN, NCCN, FIGO, AUC, VIN, dVIN, HSIL, STIC, EOC, HGSC, PD-L1 and SCS
Page and Line Numbering
Please include page numbering and continuous line numbering in the manuscript document.
Word Count
The word count excludes the title page, abstract, tables, acknowledgements and contributions and the references. If you are not a native English speaker and would like assistance with your article there is a professional editing service available.
Excluded Article Types
The IJGC is not currently accepting submissions on breast cancer. Additionally, given the high volume of submissions on the subject of HPV and pre-invasive disease of the lower genital tract, we will restrict consideration for review and ultimate publication to those manuscripts reflecting novel data from either large prospective trials or high-level scientific multi-institutional efforts reflecting a high number of patients. We will also give higher priority to work that is impacting a segment or region of the world where HPV has been limited. Manuscripts reflecting findings that have already been published by others with similar results will not be considered for review and will be returned to authors.
Editors as Authors
When a paper has been submitted from the Editor, Deputy or Associate Editors’ departments, they have no role in the reviewing or decision-making process. This also applies to any Associate Editors who are authors, in which instance the reviewing process is handled by the Editor in Chief.
Industry Authorship
At IJGC we encourage authors to submit scientific work deemed of value to the community of gynecologic oncology and related health care areas. This includes industry-sponsored work and this may include authorship of Original Research articles by individuals directly employed by industry (that is, companies producing drugs, devices, tests, equipment or companies with an interest in the topic of the article). An individual is considered employed by industry if at least 25% of anticipated annual income is derived from a single manufacturer (as defined above). Individuals not employed by industry may submit manuscripts with the understanding that the IJGC financial disclosure policy is strictly adhered to. IJGC will not publish a manuscript if an author has any stocks or shares, equity, or a named position on a company board that is producing the product evaluated in the publication.
File Formats
When submitting to IJGC, please ensure all files are submitted correctly with the corresponding file types selected. Doing so can help reduce the amount of time before your paper receives a decision.
Specific Examples:
All tables should be submitted in the manuscript document after the references section. The main manuscript document (with tables) file should be in Word doc format.
Each figure should be uploaded as a separate “Image” file. Figures may be in TIFF, EPS, PDF, or JPEG format.
Highlights should be uploaded in one “Highlights” file. The Highlights document should be in Word doc format.
Visual Abstracts
The International Journal of Gynecologic Cancer is excited to announce that it will begin accepting visual abstracts from authors of in process or accepted manuscripts.
A visual abstract is meant to provide readers with the highlights of the article in an easy-to-read and visually engaging image.
Authors are required to use our template to create their visual abstract.
All visual abstracts should include the following:
Article Title
Full author list (institutions not necessary)
Easy-to-read and visually engaging image that highlights the findings and conclusions of the study
Visual abstracts should be in PowerPoint format.
Visual abstracts should be emailed to the Editorial Office at ijgc@jjeditorial.com within two weeks of the article being accepted for publication. Please use the email subject line “Visual Abstract for ‘[Article Title].’ Visual abstracts will be shared on IJGC’s social media channels. Please include the Twitter handles of any authors or institutions who would like to be tagged in IJGC’s social media posts about the article.
Please contact the Editorial Office at ijgc@jjeditorial.com with questions.
Article Types
Original research
Our intent is to publish high quality research as it relates to clinical trials, outcome analyses, translational research, cost utility analyses, etc. Meta-analyses and literature reviews should be submitted as Original Articles and require a PRISMA Checklist. Authors should use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for grading evidence when submitting a clinical guidelines article.
Original research should include a structured abstract of no more than 300 words with the following subsections: Introduction, Methods, Results and Discussion. The manuscript text should have the following headings: Introduction, Methods, Results and Discussion. The following statement must be included in the Methods section: In accordance with the journal’s guidelines, we will provide our data for the reproducibility of this study in other centers if such is requested.
Original research should also include a Precis of 200 characters, which should briefly provide information on the value and impact of the study. Authors should also submit 3 Highlights of no more than 100 characters each, outlining the key findings and impact of the study. Authors may also include supplemental figures and tables.
Original Research articles should include a Discussion section with the below subsections:
Summary of Main Results
In this section, authors must clearly and concretely provide the main findings of their study with a particular focus on the primary objective of the study as the first statement of the Discussion section. Subsequently, the authors should provide the main findings on any secondary objective of the study. Authors should refrain from interpreting the findings and the potential implications of their results in this section and only findings that are supported by the data presented in the Results section should be documented. It is important to highlight that information should not be repetitive and absolute data that is already presented in the Results should not be repeated in this section.
Results in the Context of Published Literature
In this section of the Discussion, the authors should provide a detailed analysis on how the results of their study either agree or disagree with the most relevant data published in the literature thus far. An evaluation of previously published studies should be focused and directed at information that either agrees or refutes the results presented in the current study. The authors should also provide fair and balanced analysis on the reasons as to why other data previously published in the literature may differ from their findings. The authors should focus their discussion on the most relevant and pertinent studies, ideally highlighting those studies with highest quality and evidence-based relevance. It is expected that authors provide details on potential gaps or flaws in the studies that are being presented from the literature.
Limitations
In this section, the authors should provide a detailed outline as to the recognized weaknesses of the study as perceived by the authors and should also reflect additional weaknesses provided by Reviewers.
Implications for Practice and Future Research
In this section, the authors should highlight details as to what is the most impacting contribution to the literature from their study. The emphasis should be on how the results of their study should impact patient care or future research directions. The primary focus should not be a reaffirmation of prior published literature and, therefore, the authors should provide clear and concrete statements as to what is the contribution to the literature from their study. A detailed, clear, and direct message regarding the gap in knowledge that is being filled with the results from their study.
Conclusions
In this section, the authors should provide a brief and concise statement regarding the overall conclusion of their study. This statement should be congruent with the results of their study. It should not be an interpretation on how the authors view their own results or how the reader should view their results, but rather a definitive statement that is comprehensive and reflects only the findings of their study. In addition, it should not be a general statement that is all-encompassing regarding the known literature, but instead it should be direct reflection of the findings of the results of their study.
Word Count: up to 2,700 words
Abstract (not including abstract or references): up to 300 words
Tables/Figures: up to 5 tables and/or figures
References: up to 35
Authors: up to 40 (no more than 8 from a single institution)